AbbVie filed suit against Galderma alleging infringement of patented dermal filler syringe designs. The litigation centers on proprietary syringe engineering—likely covering needle gauge, plunger mechanics, or delivery systems that differentiate premium filler products in the market.
Regulatory
AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs
Patent litigation over syringe technology could affect filler supply and pricing dynamics.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Get the free Inside MedSpa brief by email
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
Patent litigation over syringe design could reshape filler supply chains and pricing.
For practices, syringe patent disputes are typically long-running and rarely result in immediate supply disruption, but they signal competitive tension over product differentiation in the filler category. If AbbVie prevails or secures an injunction, Galderma could face redesign costs or temporary supply constraints on certain filler lines (Restylane, Volbella, etc.). Conversely, a Galderma win strengthens its design freedom. Practices should monitor case progress and maintain relationships with both manufacturers' account teams to understand any potential SKU changes or supply implications.
Source: original report ↗
Frequently asked questions
Will the AbbVie vs Galderma syringe patent lawsuit affect my filler supply?
Patent litigation typically takes years to resolve and rarely causes immediate supply disruption. However, if AbbVie wins or secures an injunction, Galderma could face redesign costs or temporary constraints on certain filler lines like Restylane and Volbella. Monitor case progress and stay in contact with both manufacturers' account teams for updates on potential SKU changes.
What syringe technology is AbbVie claiming Galderma infringed?
The lawsuit centers on proprietary syringe engineering, likely covering needle gauge, plunger mechanics, or delivery systems that differentiate premium filler products. AbbVie hasn't disclosed specific technical details, but these design elements are key competitive differentiators in the filler market.
Could this patent case increase dermal filler prices?
If Galderma is forced to redesign syringes or faces supply constraints, production costs could rise, potentially affecting filler pricing. However, the outcome depends entirely on the lawsuit result—a Galderma win would preserve current design freedom and pricing dynamics.
Which Galderma fillers could be impacted by this lawsuit?
Restylane and Volbella are the primary Galderma filler lines that could face supply or redesign implications if AbbVie prevails. Other Galderma filler products may also be affected depending on which syringe designs are covered by the patent.
How long does a dermal filler patent lawsuit typically take?
Syringe patent disputes are typically long-running, often taking multiple years to resolve through litigation or settlement. Practices should not expect immediate outcomes, but should maintain communication with account teams to stay informed of any developments.
Business information, not medical or legal advice. Verify product status at FDA.gov.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.